Cardiac-directed expression of adenylyl cyclase reverses electrical remodeling in cardiomyopathy

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 1, 2006, Pages 170-181

  Timofeyev, Valeriy ^a   He, Yuxia ^a   Tuteja, Dipika ^a   Zhang, Qian ^a   Roth, David M ^b,c   Hammond, H Kirk ^b,d   Chiamvimonvat, Nipavan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University of California   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Adenylyl cyclase; Cardiomyopathy; Electrical remodeling; K current

Indexed keywords

ADENYLATE CYCLASE; GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; ELECTROCARDIOGRAPHY MONITORING; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; MOUSE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENYLATE CYCLASE; ANIMALS; CARDIOMEGALY; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; ELECTRIC STIMULATION; GENE EXPRESSION REGULATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; MICE; MICE, TRANSGENIC; POTASSIUM CHANNELS; UP-REGULATION; VENTRICULAR REMODELING;

ANIMALIA; MAMMALIA; MUS MUSCULUS;

EID: 33745403208     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.04.008     Document Type: Article

References (52)

1. Ho K.K., Pinsky J.L., Kannel W.B., and Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22 (1993) 6A-13A
2. Molkentin J.D., Dorn G.W., and I. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001) 391-426
3. Frey N., and Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65 (2003) 45-79
4. Birnbaumer L., and Rodbell M. Adenylyl cyclase in fat cells: II. Hormone receptors. J Biol Chem 244 (1969) 3477-3482
5. Krell M.J., Kline E.M., Bates E.R., Hodgson J.M., Dilworth L.R., Laufer N., et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 112 (1986) 787-791
6. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 (1991) 1468-1475
7. Bohm M., Reiger B., Schwinger R.H., and Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res 28 (1994) 1713-1719
8. Lai N.C., Roth D.M., Gao M.H., Fine S., Head B.P., Zhu J., et al. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricularfunction and cAMP-generating capacity. Circulation 102 (2000) 2396-2401
9. Gao M.H., Lai N.C., Roth D.M., Zhou J., Zhu J., Anzai T., et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation 99 (1999) 1618-1622
10. Roth D.M., Gao M.H., Lai N.C., Drumm J., Dalton N., Zhou J.Y., et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 99 (1999) 3099-3102
11. Roth D.M., Bayat H., Drumm J.D., Gao M.H., Swaney J.S., Ander A., et al. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 105 (2002) 1989-1994
12. Engelhardt S., Hein L., Wiesmann F., and Lohse M.J. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 96 (1999) 7059-7064
13. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101 (2000) 1707-1714
14. Iwase M., Uechi M., Vatner D.E., Asai K., Shannon R.P., Kudej R.K., et al. Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Physiol 272 (1997) H585-H589
15. Yatani A., Frank K., Sako H., Kranias E.G., Dorn G.W., and I. Cardiac-specific overexpression of Galphaq alters excitation-contraction coupling in isolated cardiac myocytes. J Mol Cell Cardiol 31 (1999) 1327-1336
16. q. Am J Physiol, Heart Circ Physiol 279 (2000) H139-H148
17. D'Angelo D.D., Sakata Y., Lorenz J.N., Boivin G.P., Walsh R.A., Liggett S.B., et al. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 94 (1997) 8121-8126
18. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 (2005) 214-222
19. 1D) calcium channel in sinoatrial nodes: insight gained using gene-targeted null mutant mice. Circ Res 90 (2002) 981-987
20. + channel expression and activity: novel insights from genetically altered mice. J Physiol 562 (2005) 745-758
21. Mitchell G.F., Jeron A., and Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol 274 (1998) H747-H751
22. + channel via protein kinase A and protein kinase G. Circ Res 89 (2001) 1005-1013
23. 2+ cycling proteins underlie cardiac action potential prolongation in a pressure-overloaded guinea pig model with cardiac hypertrophy and failure. Circ Res 86 (2000) 558-570
24. Hamill O., Marty A., Neher E., Sakmann B., and Sigworth F. Improved patch clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 391 (1981) 85-100
25. + currents in adult mouse ventricular myocytes. J Gen Physiol 113 (1999) 661-678
26. αq-mediated cardiac hypertrophy and ventricular dysfunction. Mol Pharmacol 57 (2000) 278-287
27. + current, by PKC. Am J Physiol 273 (1997) H1775-H1786
28. + currents in rat ventricular myocytes and its modification by hormonal status. J Physiol 520 Pt2 (1999) 439-449
29. Clerk A., and Sugden P.H. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ Res 86 (2000) 1019-1023
30. Tomaselli G.F., and Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 42 (1999) 270-283
31. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 73 (1993) 379-385
32. Kääb S., Nuss H., Chiamvimonvat N., O'Rourke B., Pak P., Kass D., et al. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 78 (1996) 262-273
33. Näbauer M., Beuckelmann D., and Erdmann E. Characteristics of transient outward current in human ventricular myocytes from patients with terminal heart failure. Circ Res 73 (1993) 386-394
34. Wickenden A.D., Kaprielian R., Kassiri Z., Tsoporis J.N., Tsushima R., Fishman G.I., et al. The role of action potential prolongation and altered intracellular calcium handling in the pathogenesis of heart failure. Cardiovasc Res 37 (1998) 312-323
35. Zobel C., Kassiri Z., Nguyen T.T., Meng Y., and Backx P.H. Prevention of hypertrophy by overexpression of Kv4.2 in cultured neonatal cardiomyocytes. Circulation 106 (2002) 2385-2391
36. Barry W.H., and Gilbert E.M. How do beta-blockers improve ventricular function in patients with congestive heart failure?. Circulation 107 (2003) 2395-2397
37. 2+-ATPase delays myocardial failure after myocardial infarction inrats at a cost of increased acute arrhythmias. Circulation 109 (2004) 1898-1903
38. Sunahara R.K., Dessauer C.W., and Gilman A.G. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36 (1996) 461-480
39. αq-overexpressing mice. Proc Natl Acad Sci U S A 96 (1999) 6400-6405
40. Tang T., Gao M.H., Roth D.M., Guo T., and Hammond H.K. Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy. Am J Physiol, Heart Circ Physiol 287 (2004) H1906-H1912
41. Feldman A.M. Adenylyl cyclase: a new target for heart failure therapeutics. Circulation 105 (2002) 1876-1878
42. Kawabe J., Ebina T., Toya Y., Oka N., Schwencke C., Duzic E., et al. Regulation of type V adenylyl cyclase by PMA-sensitive and -insensitive protein kinase C isoenzymes in intact cells. FEBS Lett 384 (1996) 273-276
43. Chen J., and Iyengar R. Inhibition of cloned adenylyl cyclases by mutant-activated Gi-alpha and specific suppression of type 2 adenylyl cyclase inhibition by phorbol ester treatment. J Biol Chem 268 (1993) 12253-12256
44. s-stimulated adenylyl cyclases by phorbol ester treatment. J Biol Chem 268 (1993) 3829-3832
45. Yoshimura M., and Cooper D.M. Type-specific stimulation of adenylylcyclase by protein kinase C. J Biol Chem 268 (1993) 4604-4607
46. Lai H.L., Lin T.H., Kao Y.Y., Lin W.J., Hwang M.J., and Chern Y. The N terminus domain of type VI adenylyl cyclase mediates its inhibition by protein kinase C. Mol Pharmacol 56 (1999) 644-650
47. α11 in cardiomyocytes. Nat Med 7 (2001) 1236-1240
48. Okumura S., Takagi G., Kawabe J., Yang G., Lee M.C., Hong C., et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci U S A 100 (2003) 9986-9990
49. Gao M., Ping P., Post S., Insel P.A., Tang R., and Hammond H.K. Increased expression of adenylylcyclase type VI proportionately increases beta-adrenergic receptor-stimulated production of cAMP in neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A 95 (1998) 1038-1043
50. Tepe N.M., Lorenz J.N., Yatani A., Dash R., Kranias E.G., Dorn G.W., and I. Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signalling. Biochemistry 38 (1999) 16706-16713
51. 2+ current in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J 16 (2002) 1636-1638
52. Okumura S., Kawabe J., Yatani A., Takagi G., Lee M.C., Hong C., et al. Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res 93 (2003) 364-371